This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Capitano, B.
Right arrow Articles by Venkataramanan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capitano, B.
Right arrow Articles by Venkataramanan, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2006, p. 1878-1880, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1878-1880.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Intrapulmonary Penetration of Voriconazole in Patients Receiving an Oral Prophylactic Regimen

Blair Capitano,1,2* Brian A. Potoski,1,2 Shahid Husain,2 Shimin Zhang,1 David L. Paterson,2 Sean M. Studer,3 Kenneth R. McCurry,4 and Raman Venkataramanan1,5

School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania,1 Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania,2 Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania,3 Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania,4 Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania5

Received 6 October 2005/ Returned for modification 4 December 2005/ Accepted 13 February 2006

Voriconazole penetrated well into the pulmonary epithelial lining fluid (ELF) in lung transplant patients receiving oral prophylaxis. The ELF concentrations exceeded those of the plasma, with an average ELF-to-plasma ratio of 11 (±8). A strong association between plasma and ELF concentrations (r2 = 0.95) was noted.

* Corresponding author. Mailing address: School of Pharmacy, University of Pittsburgh, 720 Salk Hall, 3501 Terrace St., Pittsburgh, PA 15261. Phone: (412) 648-9629. Fax: (412) 624-8175. E-mail: capitanob{at}upmc.edu.

Antimicrobial Agents and Chemotherapy, May 2006, p. 1878-1880, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1878-1880.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  
  • Weiler, S., Falkensammer, G., Hammerer-Lercher, A., Anliker, M., Vogelsinger, H., Joannidis, M., Dunzendorfer, S., Stein, M., Bellmann, R. (2009). Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid Formulations. Antimicrob. Agents Chemother. 53: 4934-4937 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., Krishna, G., McIver, M., Little, E., Zurlinden, E. (2009). Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects. Antimicrob. Agents Chemother. 53: 703-707 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»